A new article was published in CPT: Pharmacometrics Syst Pharmacol

A. Volkova, V. Sokolov, F. Tettamanti, Verma M, Y. Ugolkov, K. Peskov, Teng W, Kimko H. (2025) An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus Erythematosus. CPT Pharmacometrics Syst Pharmacol. 2025, Accepted on 18 Apr.

 A quantitative systems pharmacology model was developed to compare the pharmacodynamic effects of four type I interferon (IFN1)-targeting therapies-anifrolumab, sifalimumab, daxdilimab, and litifilimab-for systemic lupus erythematosus.

 The model, built and validated using clinical trial data, successfully captured trends in the reduction of the IFN1 gene signature (IFNGS). Key findings indicate that anifrolumab demonstrated superior potential for maximum IFNGS reduction compared to the other therapies. The model also highlighted that treatment benefit is significantly enhanced in patients with high baseline IFNGS or IFNα levels.